MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the ...

MoonLake stock has seen a 400% increase in value since its listing on the Nasdaq, and has raised over $450 million through equity offerings. Read more here.

Stocks MoonLake Immunotherapeutics-stock News for MoonLake Immunotherapeutics MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody ...

The primary endpoint of MoonLake Immunotherapeutics' HiSCR75 was met with statistical significance in the phase 2 MIRA trial. Click here for my take on MLTX stock now.

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts ...

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10. A successful year including the announcements of positive ...

Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today By Eric Volkman – Jun 27, 2023 at 6:56PM ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term ...

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions ...

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates ...

MoonLake Immunotherapeutics MLTX has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for ...

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in ...